Literature DB >> 11921322

Morality and the limits of societal values in health care allocation.

Rebecca L Walker1, Andrew W Siegel.   

Abstract

In this paper, we consider whether there is a clear moral justification for the proposal that societal value preferences (SVPs) should be included in Cost Effectiveness Analyses (CEA) of health care resource allocations. We argue, first, that proponents of the use of SVPs need to be clear about the relationship between these values and moral principles. In particular, once moral principles are accepted as ruling out some SVPs (such as those that are irrational or revealing prejudice), an account is required of why we need to appeal to SVPs rather than moral principles to determine a just division of health care resources. Secondly, we consider whether an independent moral justification might underwrite the use of SVPs. In various places in the literature the notions of representation, presumed consent and democratic decision making appear to be invoked as candidates for fulfilling this justificatory role. We discuss some problems with each of these justifications in the hope of eliciting a more comprehensive proposal from the proponents of SVPs. We conclude that, although a number of interesting proposals have been made, no compelling justification for including SVPs in CEA has yet been systematically articulated. Copyright 2002 John Wiley & Sons, Ltd.

Keywords:  Health Care and Public Health

Mesh:

Year:  2002        PMID: 11921322     DOI: 10.1002/hec.665

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  2 in total

1.  Comment on: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation".

Authors:  Afschin Gandjour
Journal:  Pharmacoeconomics       Date:  2017-05       Impact factor: 4.981

2.  One and done? Equality of opportunity and repeated access to scarce, indivisible medical resources.

Authors:  Marco D Huesch
Journal:  BMC Med Ethics       Date:  2012-05-24       Impact factor: 2.652

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.